SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue for the March 2025 quarter is pegged at Rs. 3287.53 millions, about 10.19% up against Rs. 2983.54 millions recorded during the year-ago period.The Total Profit for the quarter ended March 2025 of Rs. 275.89 millions grew from Rs.-578.68 millions Operating profit Margin for the quarter ended March 2025 improved to 497.74% as compared to -338.69% of corresponding quarter ended March 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 3287.53 2983.54 10.19 13117.84 14441.19 -9.16 13117.84 14441.19 -9.16
Other Income 320.50 266.64 20.20 1241.92 941.21 31.95 1241.92 941.21 31.95
PBIDT 497.74 -338.69 -246.96 2626.91 -325.37 -907.36 2626.91 -325.37 -907.36
Interest 26.26 47.95 -45.23 153.09 183.13 -16.40 153.09 183.13 -16.40
PBDT 471.48 -399.53 -218.01 2473.82 -702.39 -452.20 2473.82 -702.39 -452.20
Depreciation 100.93 90.86 11.08 395.45 326.94 20.95 395.45 326.94 20.95
PBT 370.55 -490.39 -175.56 2078.37 -1029.33 -301.91 2078.37 -1029.33 -301.91
TAX 94.66 88.29 7.21 468.39 625.18 -25.08 468.39 625.18 -25.08
Deferred Tax 12.05 41.29 -70.82 -7.14 141.78 -105.04 -7.14 141.78 -105.04
PAT 275.89 -578.68 -147.68 1609.98 -1654.51 -197.31 1609.98 -1654.51 -197.31
Equity 306.21 286.13 7.02 306.21 286.13 7.02 306.21 286.13 7.02
PBIDTM(%) 15.14 -11.35 -233.37 20.03 -2.25 -988.80 20.03 -2.25 -988.80

Akums Drugs & Pharma Share Price

534.10 0.75 (0.14%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×